Switch theme
Sign up to access all valuation multiples
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
2013
32
LTM Revenue $30.6M
Last FY EBITDA -$72.5M
$94.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Spero Therapeutics has a last 12-month revenue (LTM) of $30.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Spero Therapeutics achieved revenue of $27.4M and an EBITDA of -$72.5M.
Spero Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Spero Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $30.6M | XXX | $27.4M | XXX | XXX | XXX |
| Gross Profit | $30.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$72.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -265% | XXX | XXX | XXX |
| EBIT | -$76.3M | XXX | -$72.5M | XXX | XXX | XXX |
| EBIT Margin | -250% | XXX | -265% | XXX | XXX | XXX |
| Net Profit | -$73.5M | XXX | -$68.6M | XXX | XXX | XXX |
| Net Margin | -240% | XXX | -250% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Spero Therapeutics's stock price is $3.
Spero Therapeutics has current market cap of $140M, and EV of $94.9M.
See Spero Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $94.9M | $140M | XXX | XXX | XXX | XXX | $-1.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Spero Therapeutics has market cap of $140M and EV of $94.9M.
Spero Therapeutics's trades at 3.5x EV/Revenue multiple, and -1.3x EV/EBITDA.
Equity research analysts estimate Spero Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Spero Therapeutics has a P/E ratio of -1.9x.
See valuation multiples for Spero Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $140M | XXX | $140M | XXX | XXX | XXX |
| EV (current) | $94.9M | XXX | $94.9M | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.3x | XXX | XXX | XXX |
| EV/EBIT | -1.2x | XXX | -1.3x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.9x | XXX | -2.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSpero Therapeutics's last 12 month revenue growth is -87%
Spero Therapeutics's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $3.1M for the same period.
Spero Therapeutics's rule of 40 is -60% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Spero Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Spero Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -87% | XXX | -78% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -265% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -60% | XXX | -351% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 353% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 365% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Spero Therapeutics acquired XXX companies to date.
Last acquisition by Spero Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Spero Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Spero Therapeutics founded? | Spero Therapeutics was founded in 2013. |
| Where is Spero Therapeutics headquartered? | Spero Therapeutics is headquartered in United States of America. |
| How many employees does Spero Therapeutics have? | As of today, Spero Therapeutics has 32 employees. |
| Who is the CEO of Spero Therapeutics? | Spero Therapeutics's CEO is Ms. Esther Rajavelu. |
| Is Spero Therapeutics publicy listed? | Yes, Spero Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Spero Therapeutics? | Spero Therapeutics trades under SPRO ticker. |
| When did Spero Therapeutics go public? | Spero Therapeutics went public in 2017. |
| Who are competitors of Spero Therapeutics? | Similar companies to Spero Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Spero Therapeutics? | Spero Therapeutics's current market cap is $140M |
| What is the current revenue of Spero Therapeutics? | Spero Therapeutics's last 12 months revenue is $30.6M. |
| What is the current revenue growth of Spero Therapeutics? | Spero Therapeutics revenue growth (NTM/LTM) is -87%. |
| What is the current EV/Revenue multiple of Spero Therapeutics? | Current revenue multiple of Spero Therapeutics is 3.1x. |
| Is Spero Therapeutics profitable? | Yes, Spero Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
